The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: The heart 'OMics' in AGEing (HOMAGE) randomized clinical trial

  1. Cleland, J.G.F.
  2. Ferreira, J.P.
  3. Mariottoni, B.
  4. Pellicori, P.
  5. Cuthbert, J.
  6. Verdonschot, J.A.J.
  7. Petutschnigg, J.
  8. Ahmed, F.Z.
  9. Cosmi, F.
  10. Brunner La Rocca, H.-P.
  11. Mamas, M.A.
  12. Clark, A.L.
  13. Edelmann, F.
  14. Pieske, B.
  15. Khan, J.
  16. McDonald, K.
  17. Rouet, P.
  18. Staessen, J.A.
  19. Mujaj, B.
  20. González, A.
  21. Diez, J.
  22. Hazebroek, M.
  23. Heymans, S.
  24. Latini, R.
  25. Grojean, S.
  26. Pizard, A.
  27. Girerd, N.
  28. Rossignol, P.
  29. Collier, T.J.
  30. Zannad, F.
  31. Erakutsi egile guztiak +
Aldizkaria:
European Heart Journal

ISSN: 1522-9645,  0195-668X

Argitalpen urtea: 2021

Alea: 42

Zenbakia: 6

Orrialdeak: 684-696

Mota: Artikulua

DOI: 10.1093/EURHEARTJ/EHAA758 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus